| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1113 | |
| Phytochemical name or plant extracts | Ginkgolic acid C17:2 | |
| PMID | 22380770 | |
| Literature evidence | Inhibition of fatty acid synthase by ginkgolic acids from the leaves of Ginkgo biloba and their cytotoxic activity. | |
| IUPAC name | 2-heptadeca-8,11-dienyl-6-hydroxybenzoic acid | |
| Phytochemicals’ class or type of plant extracts | Ginkgolic acid | |
| Source of phytochemicals or plant Extracts | Ginkgo biloba | |
| Geographical availability | China Southeast | |
| Plant parts | Leaves | |
| Other cancers | Breast cancer, Lung cancer, Leukemia | |
| Target gene or protein | FAS | |
| Gene or Protein evidence | As demonstrated in this study, ginkgolic acids C15:1 (1), C17:2 (2), and C17:1 (3) were capable of inhibiting FAS activity, which might provide a new insight into the mechanism underlying the anticancer potential of ginkgolic acids and related alkylphenols. | |
| Target pathways | NA | |
| IC50 | 108.2 µM against MCF-7 | |
| Potency | Although GA are known to possess a contact allergic potential, they can be considered as interesting non-cytotoxic anticancer agents, from which breast cancer patients might benefit, especially if used in combination with other anticancer drugs. | |
| Cell line/ mice model | MCF-7, A549, HL-60 | |
| Additional information | The use of extract from Ginkgo biloba for treatment of conditions associated with impaired blood circulation, e.g. debilitated brain function, hearing loss, vertigo and tinnitus is a more recent development that started in western Europe. The plant has a very good reputation for being effective against CNS problems. | |
| PubChem ID | 54147201 | |
| Additional PMIDs | 28402272 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:262125-1 | |
| Safety | NA |